Conceptual framework of modern molecular oncology paving the ways for advance targeted therapies for cancer treatments

Title: Conceptual framework of modern molecular oncology paving the ways for advance targeted therapies for cancer treatments

Author: Major Retd M.Q .Baig

DOI: https://dx.doi.org/10.18535/jmscr/v10i2.12

Abstract

Cancer cells are those cells that overcomes the boundaries of impending unrestricted divisions and will multiply and further sustain aberrations that’s fuel its growth, survival, invasion and migration (metastasis) to established its presence in distant organs. Technologies have emerged that facilitate understanding of pathways which got disturbed leading the cause of cancer genesis it also opens the gate for targeted therapies that targets specific molecules in the pathways of cancer genesis and its further divisions like few examples , Gleeve which inhibits a subset of tyrosin kinase is approved for the treatment of CML,GIST tumors, Irresa which inhibits EGFR used in NSCLC, Herceptin an monoclonal antibody used in her-2 neu positive breast cancer treatment, Valcade, a Proteosome inhibitor that elicits programmed cell death is approved for the treatment of Multiple myeloma treatment .many more drugs are currently under trails .

Keywords: Targeted therapies, Metastasis, Migrations.

References

Perkins, N. D. Oncogenes, tumor suppressors and p52 NF-B. Oncogene 22,7553–7556 (2003).
Lin, L., DeMartino, G. N. & Greene, W. C. Cotranslational biogenesis of NF-B p50 by the 26S proteasome. Cell 92, 819–828 (1998).
Cohen, S., Achbert-Weiner, H. & Ciechanover, A. Dual effects of Bkinase mediated phosphorylation on p105 fate: SCF(TrCP)-dependent degradation and SCF (TrCP)-independent processing. Mol. Cell. Biol. 24, 475–486 (2004).

Druker Brian J., et al. "Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia." The New England Journal of Medicine 344, no. 14 (2001): 1031–1037.
Goldman, John M., and Junia V. Melo. "Targeting the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia." The New England Journal of Medicine 344, no. 14 (2001): 1084–1086.
Nowell, P., J. Rowley, and A. Knudson. "Cancer Genetics, Cytogenetics—Defining the Enemy Within." Nature Medicine 4 (October 1998): 1107–1114.

Call For Paper Volume 12 Issue 12 December 2024

The JMSCR is accepting manuscripts for its coming issues to be Publish Volume 12 Issue 12 December 2024 the JMSCR invites authors to submit manuscripts Reporting original medical research, original article, research article, case report, systematic reviews, or educational Innovations for publication for the coming issues that will be released in Volume 12 Issue 12 December 2024. Types of manuscripts suitable for JMSCR include: Medical research, Clinical research Educational Innovation, Brief Report, Reviews on Teaching In keeping with high quality scholarship, Read More.....

https://jmscr.igmpublication.org/ems/index.php/jmscr/about/submissions

If any difficulty you can also submit to: This email address is being protected from spambots. You need JavaScript enabled to view it.

JMSCR Menu

Impact Factor SJIF 2024: 7.892

https://sjifactor.com/passport.php?id=1725

Crossref - DOI

Crossref - DOI Prefix: 10.18535/jmscr

Editorial Policy

Authors should prepare their manuscripts according to the instructions given in the authors' guidelines. Manuscripts which do not ..

Frequency of Publication

JMSCR is published as monthly journal with 12 issues per year. Special editions are also planned subjected to the scope and need....

Submission of Articles

Authors are invited to submit their research articles, review papers, Case Report properly formatted as per the author guidelines.........

Search